BioAge Labs has appointed former GSK CEO Jean-Pierre Garnier as chair of its board of directors, bringing the pharma veteran back into the anti-aging space 16 years after he made a big bet on the ...

“JP brings exceptional operational and leadership experience as BioAge advances its pipeline for metabolic diseases.” Garnier served as the Chief Executive Officer of GlaxoSmithKline ...

Garnier will succeed current Board Chair James Healy, MD, PhD, managing partner of Sofinnova Investments, who will remain on the Board.

That fact was brought into stark focus again in early December when UK-based GSK announced plans to lay off 900 of its 2,500 R&D people in RTP. The huge global company has about 4,300 Triangle area ...

GSK has signed a research collaboration and license agreement worth over US $335 million with the University of Texas MD Anderson Cancer Center, to develop new therapeutic antibodies that promote ...